Denali Starts Dosing in Phase II Parkinson's Disease Study [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor, is being evaluated in participants with LRRK2-associated Parkinson's disease (LRRK2-PD). Shares of DNLI have risen 8.7% year to date against the industry's 8.4% decline. Image Source: Zacks Investment Research The phase IIa study will evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing. The study is designed to enroll participants into a double-blind treatment period of three months followed by an open-label extension. Denali holds the investigational new drug application for this phase IIa study and is leading its design and execution. This study is being funded under a collaboration and development funding agreement between Denali and a third party. In January 2024, Denali entered into a funding agreement with an unrelated third party, whereby this
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- Denali Therapeutics Inc. (NASDAQ: DNLI) was upgraded by analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.MarketBeat
- Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s DiseaseGlobeNewswire
- Denali Has A Neurodegenerative Edge Despite Market Skepticism [Seeking Alpha]Seeking Alpha
DNLI
Earnings
- 11/6/24 - Miss
DNLI
Sec Filings
- 11/27/24 - Form 4
- 11/26/24 - Form 4
- 11/18/24 - Form 8-K
- DNLI's page on the SEC website